Form 4: Jasper Therapeutics Officer Acquires 50,000 Stock Options
SEC Form 4 Filing
Edwin Jonathan Tucker, Chief Medical Officer of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025.
Summary
- Edwin Jonathan Tucker, the Chief Medical Officer of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025.
- The exercise price of these options is $6.20.
- The options vest over a four-year period, starting February 13, 2026, with 1/4th vesting initially and the remainder vesting monthly thereafter, contingent upon continuous service.
- The options expire on February 13, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders, incentivizing him to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of the stock option grant. |
| 02/13/2026 | First vesting date for the stock options (1/4th of the shares). |
| 02/13/2035 | Expiration date of the stock options. |
| 02/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.